 Cisplatin
"Cisplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
| Descriptor ID |
D002945
|
| MeSH Number(s) |
D01.210.375 D01.625.125 D01.710.100
|
| Concept/Terms |
Cisplatin- Cisplatin
- cis-Diamminedichloroplatinum(II)
- Platinum Diamminodichloride
- Diamminodichloride, Platinum
- cis-Platinum
- cis Platinum
- Dichlorodiammineplatinum
- cis-Diamminedichloroplatinum
- cis Diamminedichloroplatinum
- cis-Dichlorodiammineplatinum(II)
|
Below are MeSH descriptors whose meaning is more general than "Cisplatin".
Below are MeSH descriptors whose meaning is more specific than "Cisplatin".
This graph shows the total number of publications written about "Cisplatin" by people in this website by year, and whether "Cisplatin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 4 | 4 | | 1996 | 1 | 4 | 5 | | 1997 | 1 | 5 | 6 | | 1998 | 1 | 1 | 2 | | 1999 | 0 | 4 | 4 | | 2000 | 0 | 3 | 3 | | 2001 | 0 | 6 | 6 | | 2002 | 1 | 6 | 7 | | 2003 | 1 | 2 | 3 | | 2004 | 2 | 3 | 5 | | 2005 | 1 | 4 | 5 | | 2006 | 1 | 5 | 6 | | 2007 | 5 | 3 | 8 | | 2008 | 2 | 3 | 5 | | 2009 | 1 | 3 | 4 | | 2010 | 0 | 7 | 7 | | 2011 | 0 | 4 | 4 | | 2012 | 2 | 6 | 8 | | 2013 | 3 | 6 | 9 | | 2014 | 3 | 5 | 8 | | 2015 | 2 | 5 | 7 | | 2016 | 2 | 11 | 13 | | 2017 | 3 | 7 | 10 | | 2018 | 3 | 3 | 6 | | 2019 | 2 | 4 | 6 | | 2020 | 2 | 3 | 5 | | 2021 | 1 | 4 | 5 | | 2022 | 3 | 4 | 7 | | 2023 | 1 | 4 | 5 | | 2024 | 12 | 5 | 17 | | 2025 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Cisplatin" by people in Profiles.
-
Yamashita T, Fujimasa K, Otsuka K, Saito A, Kohmoto M, Motegi K, Ariyoshi T, Goto S, Yamochi T, Takimoto M, Hirasawa Y, Kubota Y, Yoshimura K, Tsunoda T, Murakami M, Aoki T. Efficacy of Esophagectomy Following Neoadjuvant Chemotherapy for Esophageal Neuroendocrine Carcinoma. Anticancer Res. 2025 May; 45(5):2051-2058.
-
Freyer DR, Ohlsen TJD, Don D, Orgel E, Hayashi RJ, Lieu JE, Foster JH, Sitton MS, Geller JI, Choo DI, Rangaswami A, Chang KW, Greffe B, Chan K, Lee A, Grunstein E, O'Neill AF, Rahbar R, Anderson JJ. Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical Trial. Pediatr Blood Cancer. 2025 Jun; 72(6):e31680.
-
Thompson LE, Ghimire A, Wen X, Kim C, Doherty CL, Buckley BT, Bowles DW, O'Bryant CL, Jaimes EA, Aleksunes LM, Joy MS. Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5-HT3 Antagonist Antiemetic Drugs. J Clin Pharmacol. 2025 Jun; 65(6):763-778.
-
Matei DE, Enserro DM, Randall ME, Mutch D, Small W, DiSilvestro PA, Spirtos NM, O'Malley DM, Cantuaria GH, Michelin D, Waggoner S, Shahin M, Guntupalli S, Lara O, Ueland FR, Warshal D, Bonebrake A, Tewari KS, Tan A, Powell MA, Walker JL, Santin AD, Kim JH, Miller DS. Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma. J Clin Oncol. 2025 Mar 20; 43(9):1055-1060.
-
Feldman LER, Mohapatra S, Jones RT, Scholtes M, Tilton CB, Orman MV, Joshi M, Deiter CS, Broneske TP, Qu F, Gutierrez C, Ye H, Clambey ET, Parker S, Mahmoudi T, Zuiverloon T, Costello JC, Theodorescu D. Regulation of volume-regulated anion channels alters sensitivity to platinum chemotherapy. Sci Adv. 2024 Dec 13; 10(50):eadr9364.
-
Thompson LE, Joy MS. Understanding Cisplatin Pharmacokinetics and Toxicodynamics to Predict and Prevent Kidney Injury. J Pharmacol Exp Ther. 2024 Nov 19; 391(3):399-414.
-
Iyer G, Tangen CM, Sarfaty M, Regazzi AM, Lee IL, Fong M, Choi W, Dinney CPN, Flaig TW, Thompson IM, Lerner SP, McConkey DJ, Rosenberg JE. DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precis Oncol. 2024 Nov; 8:e2400287.
-
Xiang JJ, Campbell MT, Tu SM, Araujo J, Nieto Y, Lin JK, Xiao L, Shah AY, Wang J. Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors. Clin Genitourin Cancer. 2024 Dec; 22(6):102242.
-
Abu-Arja MH, Brown AL, Su JM, Okcu MF, Lindsay HB, McGovern SL, McAleer MF, Grosshans DR, Chintagumpala MM, Paulino AC. The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
-
Concannon KF, Glisson BS, Doebele RC, Huang C, Marotti M, Camidge DR, Heymach JV. A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2024 Nov; 25(7):601-611.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|